Raltegravir Intensification in Antiretroviral-Treated Patients Exhibiting a Suboptimal CD4+T Cell Response

Investigator: Steven Deeks, MD
Sponsor: Merck and Co., Inc.

Location(s): United States


The factors influencing the maintenance of the latent reservoir in patients with suboptimal immune recovery despite treatment-mediated viral suppression are unclear. We conducted a randomized, double-blinded, placebo-controlled study of raltegravir intensification to assess whether residual viral replication contributes to the replenishment of the latent reservoir, and assessed whether HIV-specific T cell responses in gut-associated lymphoid tissue (GALT) may limit the size of the latent reservoir.